Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone

Anesthesiology

Volumn 110, Issue 6, 2009, Pages 1371-1378

  Nieminen, Tuija H ^a   Hagelberg, Nora M ^a   Saari, Teijo I ^a   Pertovaara, Antti ^b   Neuvonen, Mikko ^b   Laine, Kari ^c   Neuvonen, Pertti J ^b   Olkkola, Klaus T ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; DRUG METABOLITE; NOROXYCODONE; NOROXYMORPHONE; OXYCODONE; OXYMORPHONE; RIFAMPICIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; NARCOTIC ANALGESIC AGENT;

ADULT; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COLD SENSITIVITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INDUCTION; FEMALE; HEAT SENSITIVITY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NOCICEPTION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; BIOAVAILABILITY; BIOSYNTHESIS; BLOOD; DOUBLE BLIND PROCEDURE; DRUG INTERACTION; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; ANALGESICS, OPIOID; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENZYME INDUCTION; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; OXYCODONE; RIFAMPIN; YOUNG ADULT;

EID: 67049159390     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e31819faa54     Document Type: Article

References (45)

1. Kalso E: Oxycodone. J Pain Symptom Manage 2005; 29:S47-56
2. Pöyhiä R, Seppäiä T, Olkkola KT, Kalso E: The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. BrJ Clin Pharmacol 1992; 33:617-21
3. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 2004; 32:447-54
4. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD: Pharma- cokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites. Clin Pharmacol Ther 2006; 79:461-79
5. Pö R, Olkkola KT, Seppä T, Kalso E: The pharmacokinetics of oxycodone after intravenous injection in adults. BrJ Clin Pharmacol 1991; 32:516-8
6. Kirvelä M, Lindgren L, Seppä T, Olkkola KT: The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 1996; 8:13-8
7. Lee HK, Lewis LD, Tsongalis GJ, McMullin M, Schur BC, Wong SH, Yeo KT: Negative urine opioid screening caused by rifampin-mediated induction of oxy- codone hepatic metabolism. Clin Chim Acta 2006; 367:196-200
8. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT: Pharmacoki- netic interactions with rifampicin: Clinical relevance. Clin Pharmacokinet 2003;42:819-50
9. Kreek MJ, GarfieldJW, Gutjahr CL, Giusti LM: Rifampin-induced methadone withdrawal. N Engl J Med 1976; 294:1104-6
10. Raistrick D, Hay A, Wolff K: Methadone maintenance and tuberculosis treatment. BMJ 1996; 313:925-6
11. Kharasch ED, Russell M, Mautz D, Thummel KE, Kunze KL, Bowdle A, Cox K: The role of cytochrome P450 3A4 in alfentanil clearance: Implications for interindividual variability in disposition and perioperative drug interactions. ANESTHESIOLOGY 1997; 87:36-50
12. Ohnhaus EE, Brockmeyer N, Dylewicz P, Habicht H: The effect of anti- pyrine and rifampin on the metabolism of diazepam. Clin Pharmacol Ther 1987; 42:148-56
13. Backman JT, Kivistö KT, Olkkola KT, Neuvonen PJ: The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 1998; 54:53-8
14. Villikka K, Kivistö KT, Backman JT, Olkkola KT, Neuvonen PJ: Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther 1997; 61:8-14
15. Lamberg TS, Kivistoö KT, Neuvonen PJ: Concentrations and effects of buspirone are considerably reduced by rifampicin. Br J Clin Pharmacol 1998;45:381-5
16. Kyrklund C, Backman JT, Kivistoö KT, Neuvonen M, Laitila J, Neuvonen PJ: Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000; 68:592-7
17. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ: Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 2005; 78:154-67
18. Paulozzi LJ: Opioid analgesic involvement in drug abuse deaths in American metropolitan areas. Am J Public Health 2006; 96:1755-7
19. Sistonen J, Fuselli S, Levo A, Sajantila A: CYP2D6 genotyping by a multiplex primer extension reaction. Clin Chem 2005; 51:1291-5
20. Michna E, Ross EL, Hynes WL, Nedeljkovic SS, Soumekh S, Janfaza D,Palombi D, Jamison RN: Predicting aberrant drug behaviour in patients treated for cancer pain: Importance of abuse history. J Pain Symptom Manage 2004;28:250-8
21. Neuvonen M, Neuvonen PJ: Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatogra- phy-electrospray-tandem mass spectrometry. Ther Drug Monit 2008; 30:333-40
22. Bond A, Lader M: The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974; 47:211-8
23. Hannington-Kiff JG: Measurements of recovery from outpatient general anaesthesia with a simple ocular test. BMJ 1970; 3:132-5
24. Stone BM: Pencil and paper tests: Sensitivity to psychotropic drugs. Br J Clin Pharmacol 1984; 18: 15S-20S
25. Cogan DG: Simplified entoptic pupillometer. Am J Ophthalmol 1941;24:1431-3
26. Backman JT, Olkkola KT, Neuvonen PJ: Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996;59:7-13
27. Jokinen MJ, Olkkola KT, Ahonen J, Neuvonen PJ: Effect of rifampin and tobacco smoking on the pharmacokinetics of ropivacaine. Clin Pharmacol Ther 2001; 70:344-50
28. Greiner B, Eichelbaum M, Fritz P, KreichgrauerHP, von Richter O, Zundler J, Kroemer HK: The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104:147-53
29. Schinkel AH, Wagenaar E, Mol CA, van Deemter L: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97:2517-24
30. KalvassJC, Olson ER, Pollack GM: Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception. Drug Metab Dispos 2007; 35:455-9
31. Kharasch ED, Hoffer C, Altuntas TG, Whittington D: Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. J Clin Pharmacol 2004; 44:224-33
32. Kharasch ED, Hoffer C, Whittington D, Sheffels P: Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther 2003; 74:543-54
33. Kharasch ED, Hoffer C, Whittington D: The effect of quinidine, used as probe for the involvement of P-glycoprotein on the intestinal absorption and pharmacodynamics of methadone. Br J Clin Pharmacol 2004; 57:600-10
34. Boström E, Simonsson USH, Hammarlund-Udenaes M: Oxycodone phar- macokinetics and pharmacodynamics in the rat in the presence of the P-glyco- protein inhibitor PSC833. J Pharm Sci 2005; 94:1060-6
35. Hassan HE, Myers AL, Lee IJ, Coop A, Eddington ND: Oxycodone induces overexpression of P-Glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats. J Pharm Sci 2007; 96:2494-506
36. Heiskanen T, Olkkola KT, Kalso E: Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998; 64:603-11
37. Caraco Y, Sheller J, Wood AJJ: Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J Pharmacol Ther 1996; 278:1165-74
38. Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C: The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol 1986; 22:49-53
39. Gimbel J, Ahdieh H: The efficacy and safety of oral immediate release oxymorphone for postsurgical pain. Anesth Analg 2005; 9:1472-7
40. Hale ME, Dvergsten C, Gimbel J: Efficacy and safety of oxymorphone extended release in chronic low back pain: Results of a randomized, doubleblind, placebo- and active-controlled phase III study. J Pain 2005; 6:21-8
41. Sloan P, Slatkin N, Ahdieh H: Effectiveness and safety of oral extended- release oxymorphone for the treatment of cancer pain: A pilot study. Support Care Cancer 2005; 13:57-65
42. Grach M, Massalha W, Pud D, Adler R, Eisenberg E: Can coadministration of oxycodone and morphine produce analgesic synergy in humans? An experimental cold pain study. Br J Clin Pharmacol 2004; 58:235-42
43. Staahl C, Christrup LL, Andersen SD, Arendt-Nielsen L, Drewes AM: A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model. Pain 2006; 123:28-36
44. Staahl C, Upton R, Foster DJ, Christrup LL, Kristensen K, Hansen SH, Arendt-Nielsen L, Drewes AM: Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone concentrations and analgesic effect in a multimodal experimental pain model. J Clin Pharmacol 2008; 48:619-31
45. Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED: Role of CYP2B6 in stereoselective human methadone metabolism. ANESTHESIOLOGY 2008; 108:363-74